drugset / Trial / NCT07570173
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
RandomizedParallel-groupSingle-blindTreatment
Summary
Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This trial will compare MK-1045 to a standard immunotherapy called blinatumomab. The goals of this trial are to learn if more people who receive MK-1045 have no cancer cells in their bone marrow compared to people who receive blinatumomab and if people who receive MK-1045 live longer compared to people who receive blinatumomab.
Timeline
- Start
- 2026-05-18
- Primary completion
- 2033-10-18
- Completion
- 2033-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Blinatumomab | Monoclonal antibody | — | Intravenous |
| Subject | MK-1045 | Other / unclassified | — | Intravenous |
| Background | Acetaminophen | Small molecule | — | Oral |
| Background | Avtozma | Unknown | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Intravenous |
| Background | Diphenhydramine | Small molecule | — | Intravenous |
| Background | Siltuximab | Monoclonal antibody | — | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | — | Intravenous |